WGS — GeneDx Holdings Corp. Stock Price, Chart & AI Report

Negative Jul 17, 2026 • 23:45 UTC GlobeNewswire Inc. • Rosen Law Firm

WGS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

A securities class action lawsuit has been filed against GeneDx Holdings Corp. for alleged misrepresentations regarding the Fabric acquisition's impact on the company's business. Investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The lead plaintiff deadline is August 3, 2026.

WGS WGSWW securities class action GeneDx Holdings Corp. Fabric acquisition misrepresentation investor compensation lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging misrepresentations and omissions regarding the Fabric acquisition. Defendants allegedly made false statements about the acquisition improving financials and creating efficiencies, while knowing of significant problems that would negatively impact the business. This resulted in investor damages.

Negative Jul 15, 2026 • 22:11 UTC GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

GeneDx Holdings Corp. Class Action Lawsuit Seeks Recovery for Investors; August 3, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making material misstatements about the viability of its $51 million acquisition of Fabric Genomics. The lawsuit covers investors who purchased WGS stock between April 16, 2025, and May 4, 2026. GeneDx's stock fell more than 49% on May 4, 2026, after the company disclosed a $31.3 million impairment loss related to Fabric and missed earnings projections. The deadline to seek lead plaintiff status is August 3, 2026.

WGS WGSWW securities fraud class action lawsuit acquisition impairment loss stock decline misrepresentation

Sentiment note

The company faces a securities fraud class action lawsuit alleging material misstatements about an acquisition's viability. The stock declined 49% after disclosing a $31.3 million impairment loss on the Fabric Genomics acquisition and missing earnings projections, indicating significant operational and financial challenges.

Negative Jul 15, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging that the company made materially false and misleading statements regarding Fabric Genomics, reimbursement rates durability, and gross margin projections during the period from April 16, 2025 to May 4, 2026. Investors who purchased GeneDx securities during this period are encouraged to join the case, with a lead plaintiff deadline of August 3, 2026.

WGS WGSWW class action lawsuit securities fraud GeneDx Holdings investor harm false statements gross margins

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions regarding business operations, margins, and reimbursement rates. These allegations of investor deception and financial misrepresentation warrant a negative sentiment rating.

Negative Jul 15, 2026 • 02:52 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings Corp. faces a securities class action lawsuit for failing to disclose material information about its acquisition performance. The company reported a significant drop in adjusted gross margin (74% to 69%), missed revenue estimates, lowered full-year guidance from $540-$550M to $475-$490M, and disclosed a $31.2M impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% on May 4, 2026. Investors who purchased shares between April 16, 2025 and May 4, 2026 have until August 3, 2026 to file lead plaintiff applications.

WGS WGSWW securities fraud class action lawsuit acquisition impairment revenue guidance reduction gross margin decline stock price decline

Sentiment note

Company faces securities fraud allegations for failing to disclose material information about acquisition performance. Significant operational deterioration evidenced by margin compression, missed revenue targets, guidance reduction, and substantial impairment charges resulted in a 49.2% stock price decline.

Negative Jul 14, 2026 • 14:50 UTC GlobeNewswire Inc. • Suewallst/Levi & Korsinsky Llp

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS

GeneDx Holdings Corp. (WGS) faces a securities class action lawsuit over alleged misleading statements regarding its Fabric Genomics acquisition. The company announced a $51 million acquisition in April 2025, but by May 2026 disclosed a $31.2 million impairment charge, a $65 million revenue guidance cut, and a 49.20% single-day stock collapse. The lead plaintiff deadline is August 3, 2026.

WGS WGSWW securities class action Fabric Genomics acquisition impairment charge revenue guidance reduction stock collapse misleading statements

Sentiment note

The company is facing a securities class action lawsuit alleging material misrepresentations about the Fabric Genomics acquisition. The acquisition deteriorated significantly from a $51 million promise to a $31.2 million write-off within 12 months, resulting in a 49.20% stock price collapse and $65 million revenue guidance reduction.

Negative Jul 13, 2026 • 22:55 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company made false and misleading statements about Fabric Genomics and margin durability. On May 4, 2026, GeneDx revealed a $57.5 million operating loss, lowered 2026 revenue guidance by $65 million, and took a $31.3 million write-down on Fabric Genomics. The stock price declined approximately 50% following the announcement.

WGS WGSWW class action lawsuit securities fraud false statements Fabric Genomics reimbursement rates goodwill write-down

Sentiment note

The company is accused of making false and misleading statements about key business segments and financial metrics. Actual Q1 2026 results revealed significant losses, substantial revenue guidance cuts, and a major write-down, resulting in a 50% stock price decline, indicating serious operational and disclosure failures.

Negative Jul 12, 2026 • 21:00 UTC GlobeNewswire Inc. • Robbins Geller Rudman & Dowd Llp

WGS INVESTOR DEADLINE: RGRD Law Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead GeneDx Class Action Lawsuit

GeneDx Holdings Corp. (NASDAQ: WGS) faces a class action lawsuit alleging that executives made false statements about the viability of its Fabric Genomics acquisition. The company revealed significant problems on May 4, 2026, including a drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss, causing the stock to plummet over 49%. Investors with substantial losses have until August 3, 2026 to seek appointment as lead plaintiff.

WGS WGSWW class action lawsuit securities fraud GeneDx Holdings Fabric Genomics acquisition stock price decline impairment loss

Sentiment note

The company is facing a securities fraud class action lawsuit for allegedly making false and misleading statements about the Fabric Genomics acquisition. The acquisition revealed significant operational and financial problems, resulting in a 49% stock price drop, reduced earnings guidance, and a substantial impairment charge.

Negative Jul 12, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging that the company made materially false and misleading statements regarding its business operations. The complaint claims GeneDx misled investors about Fabric Genomics' importance, overstated the durability of reimbursement rates, and failed to disclose that these issues would negatively impact the company's gross margins. Investors who purchased GeneDx securities between April 16, 2025 and May 4, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 3, 2026.

WGS WGSWW class action lawsuit securities fraud GeneDx Holdings investor harm false statements gross margins

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions regarding business operations, margins, and reimbursement rates. These allegations of investor deception and financial misrepresentation create significant negative sentiment.

Negative Jul 11, 2026 • 23:11 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD

Rosen Law Firm has filed class action lawsuits on behalf of investors in Insulet Corporation (PODD), GRAIL, Inc. (GRAL), and GeneDx Holdings Corp. (WGS). The lawsuits allege that defendants made false or misleading statements regarding manufacturing controls, product safety compliance, and regulatory risks. Investors who purchased securities during the specified class periods may be eligible for compensation. The lead plaintiff deadline is August 31, 2026.

PODD GRAL WGS WGSWW class action lawsuit securities fraud manufacturing defects product safety

Sentiment note

Company is subject to securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations and investor harm.

Negative Jul 11, 2026 • 22:25 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

Rosen Law Firm is encouraging investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026 to join a securities class action lawsuit. The lawsuit alleges that GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when in reality the company knew of significant viability problems that would negatively impact the business. The lead plaintiff deadline is August 3, 2026.

WGS WGSWW securities class action misrepresentation Fabric acquisition investor damages lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding the Fabric acquisition's impact on business operations and financials. Defendants allegedly knew of significant problems that would negatively impact the business but made false positive statements to investors.

Negative Jul 11, 2026 • 12:30 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

WGS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Faruqi & Faruqi, LLP is investigating a federal securities class action against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false and misleading statements about its Fabric Genomics acquisition and overstating the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555M to $475-490M, and took a $31.3M goodwill impairment charge on the $36.5M Fabric Genomics acquisition. The stock fell 49% ($33.42 per share) on the news. The deadline to seek lead plaintiff appointment is August 3, 2026.

WGS WGSWW securities class action securities fraud false statements goodwill impairment missed guidance reimbursement rates

Sentiment note

GeneDx faces a federal securities class action lawsuit alleging executives made false and misleading statements about the Fabric Genomics acquisition and reimbursement rates. The company missed Q1 earnings expectations, cut full-year guidance by approximately 12%, disclosed a $31.3M goodwill impairment on a $36.5M acquisition made one year prior, and experienced a 49% stock price decline in a single day, resulting in significant investor losses.

Negative Jul 9, 2026 • 03:02 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

A securities class action lawsuit has been filed against GeneDx Holdings Corp. for allegedly making false statements about the Fabric acquisition's impact on the company's financials and operations. Investors who purchased GeneDx stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The lead plaintiff deadline is August 3, 2026.

WGS WGSWW securities class action GeneDx Holdings Corp. Fabric acquisition misrepresentation investor compensation lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging misrepresentations and omissions regarding the Fabric acquisition's impact on business operations and financials. Defendants allegedly made false statements about cost reduction and efficiency improvements that did not materialize, causing investor damages.